Safety and immunogenicity of an anti-Middle East respiratory syndrome coronavirus DNA vaccine: a phase 1, open-label, single-arm, dose-escalation trial

BACKGROUND: Middle East respiratory syndrome (MERS) coronavirus causes a highly fatal lower-respiratory tract infection. There are as yet no licensed MERS vaccines or therapeutics. This study (WRAIR-2274) assessed the safety, tolerability, and immunogenicity of the GLS-5300 MERS coronavirus DNA vacc...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Yayımlandı:Lancet Infect Dis
Asıl Yazarlar: Modjarrad, Kayvon, Roberts, Christine C, Mills, Kristin T, Castellano, Amy R, Paolino, Kristopher, Muthumani, Kar, Reuschel, Emma L, Robb, Merlin L, Racine, Trina, Oh, Myoung-don, Lamarre, Claude, Zaidi, Faraz I, Boyer, Jean, Kudchodkar, Sagar B, Jeong, Moonsup, Darden, Janice M, Park, Young K, Scott, Paul T, Remigio, Celine, Parikh, Ajay P, Wise, Megan C, Patel, Ami, Duperret, Elizabeth K, Kim, Kevin Y, Choi, Hyeree, White, Scott, Bagarazzi, Mark, May, Jeanine M, Kane, Deborah, Lee, Hyojin, Kobinger, Gary, Michael, Nelson L, Weiner, David B, Thomas, Stephen J, Maslow, Joel N
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: Elsevier Ltd. 2019
Konular:
Articles
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC7185789/
https://ncbi.nlm.nih.gov/pubmed/31351922
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/S1473-3099(19)30266-X
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller